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Assessing HER2 gene ampliﬁcation as a potential target
for therapy in invasive urothelial bladder cancer with
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Background: This study assessed the human epidermal growth factor receptor-2 (HER2) protein expression and its
relationship with gene ampliﬁcation in invasive bladder carcinoma, using the same criteria than for breast cancer.
Patients and methods: In 1005 patients, parafﬁn-embedded tissues of transurethral resection or cystectomy were
evaluated by immunohistochemistry (IHC), using antibodies against HER2. All samples with a 2+ or 3+ HER2
overexpression were evaluated by FISH.
Results: HER2 overexpression was observed in 93 (9.2%) tumors (2+: 42 tumors and 3+: 51 tumors). Using FISH, all
HER2 3+ tumors had a gene ampliﬁcation, whereas no ampliﬁcation was found in 2+ tumors. Intratumoral
heterogeneity was observed in 35% of cases. These tumors showed the same heterogeneous pattern, with adjacent
3+ positive and negative areas by both IHC and FISH.
Conclusions: This study showed that 5.1% of invasive bladder carcinomas had a HER2 gene ampliﬁcation. These
ﬁndings may have clinical implications for the management of patients with HER2-positive locally advanced or
metastatic bladder cancer, as they could be potential candidates for targeted therapy.
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introduction
Urothelial bladder carcinoma is the fourth most common
malignancy in men and the ninth most common in women. In
the United States, 61 420 estimated new cases were expected in
2006 and >13 000 patients were likely to die. At the time of
diagnosis, 80% of urothelial bladder carcinomas are
superﬁcial and 20% of them will become invasive. Tumors that
invade the deep muscle layer of the bladder are assigned stage
T2, while T3 and T4 lesions invade the perivesical tissue and
local structures, respectively. Standard treatment of muscle-
invasive cancers has historically comprised surgical resection
achieving 5-year recurrence-free survival rates from 44% to
81%. The treatment of locally advanced or metastatic disease is
currently based on the M-VAC regimen (methotrexate,
vinblastine, doxorubicin, cisplatin), in spite of a high rate of
toxicities. Among new combinations, gemcitabine and cisplatin
(GC) confers a similar survival advantage to M-VAC,
improving the safety proﬁle [1]. Although not designed as an
equivalency trial, GC has become the ﬁrst-line treatment of
patients with locally advanced or metastatic urothelial bladder
carcinoma in many institutions. The next step in the
management of advanced urothelial bladder carcinomas is to
know whether targeted therapies could positively impact the
outcome of the disease.
The human epidermal growth factor receptor-2 (HER2) is
known to contribute to physiologic mechanisms of cell
proliferation by an intrinsic tyrosine kinase activity. The
assessment of HER2 status is crucial for the management of
breast cancer, for both prognosis and prediction of the response
to targeted therapies [2]. The introduction of trastuzumab,
a recombinant humanized mAb to the extracellular domain of
HER2, has dramatically changed the treatment of HER2-
ampliﬁed breast tumor in the adjuvant and metastatic setting
[3–5]. In breast cancer, HER2 overexpression is the result of an
ampliﬁcation of the HER2 gene, leading to an increase in HER2
messenger RNA levels and a concomitant overexpression of
the HER2 receptor on the tumor cell surface [6]. The HER2
gene is ampliﬁed in 18% of all breast cancers [7]. In invasive
urothelial bladder carcinomas, ampliﬁcation and/or
overexpression were also found. However, the true incidence of
HER2 overexpression and/or ampliﬁcation remains uncertain
ranging from 23% to 80% for overexpression [8–15] and from
0% to 32% for ampliﬁcation [10–13, 15–18]. This variability
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breast cancer, the assessment of HER2 status has to be
standardized in terms of antibodies and interpretation of the
results. In this setting, the American Society of Clinical
Oncology (ASCO) guidelines have clearly deﬁned a positive
HER2 status as an immunohistochemistry (IHC) score of 3+,
a negative HER2 status as an IHC score of 0 or 1+, and an IHC
score of 2+ had to be tested by FISH conﬁrming the HER2
status [19].
Unlike the situation in breast cancer, where the role of
HER2-targeting agents has been well established in both
metastatic and adjuvant settings, the use of HER2-targeting
agents has only emerged recently in bladder carcinomas clinical
research. A possible involvement of the HER2 receptor in the
proliferation of invasive urothelial bladder carcinomas has led
to initiate HER2-targeted therapy trials in locally advanced or
metastatic disease [20]. However, this therapeutic approach
requires a reliable evaluation of HER2 status on the basis of
robust, reproducible IHC and FISH criteria.
The aim of this retrospective study was to evaluate the HER2
protein expression and HER2 gene ampliﬁcation using the
same criteria than those used in breast cancer in a large series of
1005 patients with invasive urothelial bladder carcinoma.
patients and methods
study population and tissue specimens
A series of 1005 tumors from 1005 patients diagnosed with primary invasive
urothelial carcinoma of the urinary bladder was selected from the Cochin
Pathology Department ﬁles from 2002 to 2008 (including cases collected
from 10 centers in France for therapeutic purposes). Ten additional
metastatic lymph nodes were also included. The material poorly ﬁxed and/
or with a low cellularity had been previously ruled out. Parafﬁn-embedded
tissues were obtained after transurethral resection for bladder tumor or
cystectomy. A histologic examination on hematoxylin–eosin and saffron
(HES)-stained slides was carried out by a specialist in urologic pathology
(AV) conﬁrming the diagnosis of high-grade, muscle-invasive urothelial cell
carcinoma (Figure 1A). Pathologic stage was evaluated according to the
World Health Organization classiﬁcation.
All patients provided written informed consent for central collection of
their tissue material and clinical data for research purposes.
immunohistochemical analysis of HER2
Four-microns tissue sections prepared from a formalin-ﬁxed and parafﬁn-
embedded representative of the tumor sample were used. After
deparafﬁnization, rehydration, and antigen retrieval in citrate buffer
(10 mMol, pH 6.1), tissue sections were stained for HER2 (A0485
polyclonal antibody; Dako, Glostrup, Denmark; 1/1500). HER2 positivity
was assessed using the ASCO scoring system, evaluating only membranous
staining [19]. The interpretation of the results was on the basis of negativity
of normal tissues. The level of HER2 protein expression was assessed
semiquantitatively by the intensity and percentage of staining and scored on
a scale of 0 to 3+. Scores of 0 and 1+ are categorized as negative, 2+ as
equivocal, and 3+ as positive. The evaluation was carried out only on the
invasive component of the tumor. A score of 1+ was deﬁned as barely
perceptible membrane staining in >10% of cells, a score of 2+ was deﬁned as
weak-to-moderate complete membrane staining present in >10% of tumor
cells, and a score of 3+ was deﬁned as strong complete membrane staining
in >30% of tumor cells. A cytoplasmic staining was considered nonspeciﬁc.
The in situ component was not evaluated. Tumors presenting 2+ or 3+
HER2 expression were centrally reassayed with IHC, using the CB-11 mAb
(Novocastra, Newcastle upon Tyne, UK) as previously described [21], and
FISH was carried out in a reference laboratory for breast cancer HER2
testing (>600 FISH and 2400 IHC per year). For this second analysis, IHC
had been previously calibrated using FISH as the gold standard. Internal and
external controls (0, 1+,2 +, and 3+ breast carcinoma samples with a known
number of gene copies) were included in the experiments for each antibody.
The primary antibody, CB-11, diluted to 1/800
e, was incubated for 1 h at
22 C. Heat-induced epitope retrieval buffer was sodium citrate (pH 6.1).
Staining was revealed with the Vectastain Elite ABC peroxidase mouse IgG
kit (Vector Laboratories, Inc., Burlingame, CA) using diaminobenzidine
Figure 1. Pathologic immunohistochemistry labeling results of invasive urothelial bladder carcinoma. (A) Detrusor-invading urothelial bladder carcinoma
(hematoxylin–eosin ·40 magniﬁcation); (B) HER2 2+ membranous expression (·40 magniﬁcation); (C) HER2 3+ membranous expression (·40
magniﬁcation); and (D) patterns of heterogeneous 3+ and 2+ HER2 membranous expression within the same tumor (·20 magniﬁcation).
original article Annals of Oncology
816 | Lae ´ et al. Volume 21|No. 4|April 2010(Dako) as chromogen. Nuclei were counterstained with hematoxylin. HER2
positivity was assessed as previously described [19].
FISH analysis of HER2
Fluorescently labeled probes for both HER2-speciﬁc DNA sequences
(17q11.2–q12 region) and the centromere of chromosome 17, CEP17
(alpha satellite DNA located at locus 17p11.1q11.1), were used (HER2 FISH
PharmDx kit; Dako). The HER2 ﬂuorescent signal is usually expressed as
a ratio relative to the signal for CEP17 to evaluate gene ampliﬁcation,
polysomy 17, and to determine HER2 copy number. All samples presenting
2+ or 3+ HER2 protein expression were evaluated by FISH in the referral
laboratory, carried out on a single block according to the instructions from
the test kit manufacturer. Samples with 0/1+ staining were not tested.
Formalin-ﬁxed, parafﬁn-embedded 4-l tumor tissue sections were
deparafﬁnized and rehydrated. Sections were incubated in pretreatment
buffer at 95 C for 10 min, then in proteolytic solution at 37 C for 8 min.
Codenaturation of the probe and DNA of the tissue section was achieved
by incubation at 82 C for 5 min using a ThermoBrite automate (Abbott
Molecular Diagnostics, Rungis, France). This was followed by 15-h
hybridization at 37 C and by post-hybridization washes, according to the
protocol. Slides were mounted in di aminido phenyl indol (DAPI)/antifade.
Internal and external controls were included in the experiments. Slides
were viewed with a DAPI/rhodamine/ﬂuorescein ﬁlter, and images were
captured with a charge-coupled device camera, ﬁltered and processed with
Applied Spectral Imaging System using a Leica Microsystems microscope.
The slides were ﬁrst scanned at low magniﬁcation, using the DAPI ﬁlter, in
order to locate invasive areas, referring to the HES staining when necessary.
The number of green (corresponding to copies of chromosome 17) and
red signals (corresponding to copies of HER2 gene) was counted in at least
100 nuclei of invasive tumor cells, in two distant areas of the section at
high magniﬁcation (·1000). Three representative images per case were
captured. Tumors were classiﬁed as ampliﬁed when they showed a mean of
at least six HER2 signals, or a HER2/centromere 17 ratio >2.2, and as
nonampliﬁed when they showed a mean of less than four HER2 signals, or
when the HER2/centromere 17 ratio was <1.8 [19]. The level of HER2
ampliﬁcation in tumors was classiﬁed as follows: low ampliﬁcation (mean
7–10 signals per nucleus) or high ampliﬁcation (mean >10 signals/nucleus
or uncountable due to clusters of signals). The cut-off value of seven
copies between no ampliﬁcation and ampliﬁcation is appropriate for single-
color FISH, as it is the cut-off recommended by the ASCO/College of
American Pathologists [19]. The cut-off of 10 gene copies per nucleus
between low and high ampliﬁcation was chosen because signals can almost
always not be precisely counted over this cut-off due to clusters.
results
immunohistochemistry
Moderate-to-strong protein expression (2+ or 3+) was observed
in 115 of 1005 tumors (11.4%) using the ﬁrst IHC protocol. An
IHC 0/1+ score was detected in the remaining samples. In the
reference laboratory, using IHC analysis previously calibrated by
FISH as the gold standard, moderate-to-strong protein
expression was observed in 93 of the 115 tumors tested,
corresponding to 9.2% of the 1005 invasive urothelial bladder
carcinomas. Results are summarized in Table 1. Staining was
scored 2+ in 42 samples (2+ staining in 30%–100% of cells and
the remaining cells were scored 0) (Figure 1B) and 3+ in 51
samples(3+stainingin30%–79%ofcellsin32tumorsand80%–
100% of cells in 19 tumors) (Figure 1C). A heterogeneous 3+
staining was observed in 18 of 51 tumors (35.3%) (Figure 1D).
These tumors were characterized by areas scored 3+ (in 30%–
60% of cells) strictly and sharply separated from areas scored 2+
(12 tumors) or areas scored ‘0’ (6 tumors) (Figure 1D).
HER2 expression was concordant in 100% of cases between
metastatic lymph nodes (10 cases scored 3+ from 10 patients)
and primary bladder tumor (10 cases scored 3+). FISH was
not carried out on lymph node metastases.
FISH
Ninety-three samples scored 2+ and 3+ were analyzed by FISH
to evaluate HER2 gene copy number. Results are shown in
Table 1. All FISH analyses were informative. All of the 51 cases
with 3+ staining showed ampliﬁcation by FISH (Figure 2).
Twenty-one of the 51 tumors (41%) presented a low level of
ampliﬁcation (mean 7–10 signals per nucleus) and 30 tumors
(59%) presented a high level of ampliﬁcation (mean >10
signals/nucleus or uncountable due to clusters of signals
indicating homogeneous staining regions). Noteworthy, the
18 tumors scored 3+ with heterogeneous staining showed
exactly the same heterogeneous pattern with adjacent positive
and negative areas, detected by both IHC and FISH methods.
None of the 42 tumors with ‘2+’ staining showed ampliﬁcation
by FISH (Figure 2). Chromosome 17 polysomy was detected in
13 of the 42 tumors (31%). The remaining 29 tumors showed
two copies of HER2 and two copies of centromere 17.
discussion
In this study, 1005 primary invasive urothelial bladder
carcinomas were screened for HER2 evaluation. To our
knowledge, this is the largest multicenter series investigating
invasive urothelial bladder carcinomas by calibrated IHC and
FISH methods. A HER2 overexpression was found in 9.2% of
tumor samples. This rate is lower than those previously
described in the literature ranging from 23% to 80% [8–15].
Several hypotheses could explain these wide variations, as well
as the relatively low rate of HER2 overexpression reported here.
One of the major issues is the variability in IHC assays, related
to the heterogeneity between kits, antibodies, protocols,
interpretations or cut-off values. Discordant results reported in
the literature highlight a need for standardized laboratory
methods. The FISH method provides more objective results
than IHC because of a numerical expression. In breast cancer,
high levels of concordance (93%–100%) have been reported
between FISH and IHC [21, 22]. The present study has the
advantage of a large, retrospective, multicenter series of invasive
Table 1. Correlation between HER2 IHC staining and FISH in the 93
invasive bladder carcinomas showing HER2 overexpression (2+ and 3+)
FISH IHC positive
2+ 3+ Total
HER2 ampliﬁcation 0 51
a 51 (5.1%)
No HER2 ampliﬁcation 42 0 42 (4.2%)
Total 42 51 93 (9.2%)
aEighteen heterogeneous tumors among 51 HER2 3+ tumors.
IHC, immunohistochemistry.
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(one to two conventional slides of tumor when available). We
used the CB-11 mAb, which has demonstrated its accuracy
[21]. Our results highlight the complete concordance (100%)
between IHC and FISH analyses in bladder carcinomas, when
the same cut-off than for breast cancer is used. A quality
assurance relying on internal and external controls for HER2
IHC determination contributed to the accuracy between IHC
and FISH. IHC discordant results between two laboratories
conﬁrm that a calibration, according to FISH, appears
mandatory to ensure the validation of a given HER2 IHC
method.
Our series also indicate that a true HER2 overexpression in
bladder carcinomas result from HER2 gene ampliﬁcation, as in
breast cancer. In the present study, 5.1% of invasive urothelial
bladder carcinomas presented with a HER2 ampliﬁcation as
assessed by FISH, which was lower than rates observed in breast
cancers. These results are in agreement with those described in
the literature ranging from 0% to 32% [10–13, 15–18].
Interestingly, polysomy 17 is more common (31%) in high-
grade, muscle-invasive urothelial bladder carcinomas than in
invasive breast carcinomas (8%). Therefore, the inclusion of
a chromosome 17 probe should be recommended.
An intratumoral heterogeneity, found in 5% of invasive
breast carcinomas scored 3+ [23, 24], was more frequent in our
series of invasive urothelial bladder carcinomas scored 3+
(35%). This heterogeneity made immunohistochemical
analyses more difﬁcult to interpret than in breast cancers.
Therefore, we recommend carrying out a FISH in a reference
center in case of invasive urothelial bladder carcinoma showing
heterogeneous HER2 IHC pattern. The results of the present
study demonstrate that decision algorithms currently used in
breast cancers is also appropriate in bladder cancers.
In ovarian and breast cancers, a good concordance was
observed in HER2 status between primary tumor and distant
metastases, indicating that a HER2 clonal selection occurred
before tumor dissemination [25–27]. According to a recent
study of 53 invasive urothelial bladder carcinomas and 42
paired lymph nodes metastases, the rate of concordance was
88% for HER2 overexpression and 100% for HER2 gene
ampliﬁcation between primary tumor of the bladder and
metastatic sites, indicating that a dysregulation of this pathway
was also maintained during bladder carcinoma metastatic
spread [14]. Our ﬁndings were similar in the 10 couples of
primary and metastatic bladder carcinomas. Thereby, the
determination of HER2 status could be carried out either on
the primary tumor or on metastatic sites. Nevertheless, the
heterogeneity of HER2 overexpression in invasive urothelial
bladder carcinomas may explain differences between primary
tumor and metastases, as previously reported by Jimenez
et al. [9].
Evidence from breast cancer indicates that only tumors with
HER2 gene ampliﬁcation respond to an anti-HER2-targeted
therapy, such as trastuzumab. Using the same principle, 5%
of muscle-invasive urothelial bladder carcinomas should be
suitable for such treatment. The potential involvement of HER2
in the proliferation of urothelial carcinoma led to the initiation
of anti-HER2-targeted therapy protocols in advanced disease.
Single-agent data with trastuzumab in urothelial cancer are not
available or limited to case reports [28]. At ﬁrst glance, it
appears that the addition of trastuzumab to a three-drug
regimen (paclitaxel, carboplatin, and gemcitabine) as ﬁrst-line
treatment did not signiﬁcantly modify response rates and
median survival [29]. Lapatinib, a dual inhibitor of HER1 and
HER2 kinases, has been the subject of a single-arm, multicenter,
open-label phase II study as second-line treatment of patients
with locally advanced or metastatic urothelial bladder
carcinomas. Negative results have been recently published with
an objective response rate observed in only 1.7% of 59 patients
[30]. These disappointing results may be due to unsuitable
selection criteria, i.e. inclusion of HER2 2+ tumors not
conﬁrmed by FISH and inadequate FISH ratio cut-off. These
preliminary results highlight the need for a better patient
selection on the basis of robust and reproducible criteria. A
good response to targeted therapies requires stringent
assessment of the tumoral gene status. A French randomized,
multicenter, phase II trial of gemcitabine plus platinum salt
combined or not with trastuzumab in patients with HER2-
overpressing advanced or metastatic bladder cancer is ongoing.
In conclusion, our study showed that 5.1% of invasive
urothelial bladder carcinomas present with a HER2
ampliﬁcation. This ampliﬁcation can be assessed by
a standardized IHC, using FISH in the ambiguous cases. These
ﬁndings may have clinical implications for the management of
Figure 2. Interphase FISH on parafﬁn-embedded tumor tissue section results. (A) Nonampliﬁed tumor cells: two green ﬂuorescein isothiocyanate-labeled
(centromere 17) and two red rhodamine-labeled signals (HER2 gene) present in each nucleus and (B) tumor cells with HER2 gene ampliﬁcation: clusters of
HER2 gene signals associated with two copies of centromere 17 present in each nucleus.
original article Annals of Oncology
818 | Lae ´ et al. Volume 21|No. 4|April 2010patients with HER2-positive locally advanced or metastatic
bladder cancer. In practice, all muscle-invasive urothelial
bladder carcinomas should be tested for HER2 status according
to the recommendations for breast carcinoma [19]. The
proposed decision algorithm is to carry out calibrated HER2
IHC in all muscle-invasive urothelial bladder carcinomas as
a screening test, conﬁrmed by FISH in a reference center in case
of equivocal or heterogeneous results.
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